comparemela.com

Latest Breaking News On - Britt zocca - Page 1 : comparemela.com

Patient With Skin Cancer Receives First Dose of Novel Cancer Vaccine

A patient in a phase 2 trial has received the first dose of a novel cancer vaccine plus Keytruda for solid skin cancer tumors.

Qasim ahmadMai britt zoccaNational cancer instituteNational cancerBritt zoccaSkin cancer

Trial Underway for Vaccine-Immunotherapy Combo in Bladder Cancer

A phase 1 trial just launched, and will evaluate IO102-IO103 plus Keytruda in patients with bladder cancer whose disease is unresponsive to BCG therapy.

United statesMamta parikhCalmette guerinMai britt zoccaAmerican cancer societyUc davis school of medicineUc davis comprehensive cancer center phaseDivision of hematology oncologyBacillus calmette guerinAmerican cancerThings go wrong with cancerHematology oncologyBritt zoccaBladder cancer

First patient dosed in IO Biotech phase 1 trial of bladder cancer vaccine

IO Biotech, a clinical-stage biopharma company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has dosed the first patient in its phase 1 bladder cancer trial.

Mamta parikhMai britt zoccaUniversity of california davis comprehensive cancer centerCalifornia davis comprehensive cancer centerBritt zoccaCalifornia davis comprehensive cancerBio developmentsEmerging marketsBladder cancerClinical trial

2023 Finance And Funding Outlook Additional Insights Part 2

Additional experts weigh in on Life Science Leader's 2023 finance and funding outlook questions.

Pete oheeronDan passeriMai britt zoccaBen comerChief editorLife scienceLife science leaderDecember industry outlookBritt zocca

IO Biotech Announces Second Quarter Results for 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesNew yorkMai britt zoccaCorey davisRaena minaAmerican society of clinical oncologyCompany contactIo biotech incMerck co incAmerican association for cancer researchLifesci communicationsMerck sharp dohmeSecurities exchangeChief executive officerSecond quarterClinical oncology

vimarsana © 2020. All Rights Reserved.